Literature DB >> 19461164

MEN1 gene analysis in patients with primary hyperparathyroidism: 10-year experience of a single institution for thyroid and parathyroid care in Japan.

Minoru Kihara1, Akira Miyauchi, Yasuhiro Ito, Hiroshi Yoshida, Akihiro Miya, Kaoru Kobayashi, Yuuki Takamura, Mitsuhiro Fukushima, Hiroyuki Inoue, Takuya Higashiyama, Chisato Tomoda.   

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant hereditary disease. Primary hyperparathyroidism is known to occur at an early age in MEN1 patients. In MEN1 patients, special care regarding not only surgery for hyperparathyroidism but also other MEN1-related tumors is required. Between 1998 and 2007, 482 patients, including 16 whose hyperparathyroidism was discovered by family screening for MEN1, underwent surgical therapy for primary hyperparathyroidism at our institution. We recommended MEN1 gene analysis for patients having one of the following clinicopathological features: 1) age younger than 30 years old; 2) enlargement of multiple glands; 3) coexistence or presence of past history of MEN1-related tumors; or 4) family history of hyperparathyroidism or MEN1-related tumors. Sixty patients had at least one of the above features and were recommended for genetic analysis. Thirty-nine of these patients consented to undergo MEN1 genetic analysis and 16 (41%) showed MEN1 mutation. Pathological examination confirmed multiglandular parathyroid hyperplasia in 15 cases. Subject to this strategy, MEN1 index patients in Japan could be detected efficiently and selected for appropriate therapies for hyperparathyroidism and MEN1-related tumors.

Entities:  

Mesh:

Year:  2009        PMID: 19461164     DOI: 10.1507/endocrj.k08e-265

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  4 in total

1.  Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism.

Authors:  Lee F Starker; Tobias Akerström; William D Long; Alberto Delgado-Verdugo; Patricia Donovan; Robert Udelsman; Richard P Lifton; Tobias Carling
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

2.  Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1.

Authors:  Grzegorz Piecha; Jerzy Chudek; Andrzej Więcek
Journal:  Int J Endocrinol       Date:  2011-01-17       Impact factor: 3.257

3.  A case of Turner's syndrome with Graves' disease and primary hyperparathyroidism.

Authors:  Shigeru Nagaki; Emiko Tachikawa; Hitomi Kodama; Takao Obara; Makiko Osawa; Satoru Nagata
Journal:  SAGE Open Med Case Rep       Date:  2021-11-30

4.  A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.

Authors:  Heather Hampel; Robin L Bennett; Adam Buchanan; Rachel Pearlman; Georgia L Wiesner
Journal:  Genet Med       Date:  2014-11-13       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.